Citation Impact
Citing Papers
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
2008
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
2009
The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
2009
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
2009
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
2015
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
2007
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
2010
Astrocytes: biology and pathology
2009 Standout
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
2009
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Lung Cancer
2008 Standout
The MET axis as a therapeutic target
2009
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Transcriptional Regulation in Melanoma
2009
The molecular biology of head and neck cancer
2010 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Antibody therapy of cancer
2012 Standout
Drug development of MET inhibitors: targeting oncogene addiction and expedience
2008
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold
2011
Targeting the Met signaling pathway in renal cancer
2009
Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma
2014
C-MET as a new therapeutic target for the development of novel anticancer drugs
2010
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
2010
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
How Chemoproteomics Can Enable Drug Discovery and Development
2012
Akt signalling in health and disease
2011 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead
2009
NTRK fusion-positive cancers and TRK inhibitor therapy
2018
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
MET As a Possible Target for Non–Small-Cell Lung Cancer
2013
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1
2016
Inhibitors of the anaplastic lymphoma kinase
2012
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
2013
Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
2011
Anaplastic lymphoma kinase: signalling in development and disease
2009
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
UV Radiation and the Skin
2013 Standout
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
2008
Chemical Glycoproteomics
2016 StandoutNobel
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of Mitchell D. Nambu being referenced
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
2007
Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats
2013